Literature DB >> 23378540

EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria.

Désirée van der Heijde1, Annette H M van der Helm-van Mil, Daniel Aletaha, Clifton O Bingham, Gerd R Burmester, Maxime Dougados, Paul Emery, David Felson, Rachel Knevel, Tore K Kvien, Robert B M Landewé, Cédric Lukas, Iain McInnes, Alan J Silman, Josef S Smolen, Ewa Stanislawska-Biernat, Angela Zink, Bernard Combe.   

Abstract

The aim of this report was to propose a definition for erosive disease in the context of inflammatory arthritis in light of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) criteria for use in clinical practice and studies. A EULAR task force was formed including 16 rheumatologists and one rheumatology fellow. The process was both evidence based and consensus based, and included, between March 2010 and April 2012, analyses of data from two cohorts, two face-to-face meetings, one online voting and one teleconference. The Leiden Early Arthritis Cohort and the French ESPOIR cohort were used for the evidence-based part. The outcome measures, which were initiation of methotrexate therapy, or any disease-modifying antirheumatic drug therapy within the first year of disease and arthritis persistency over 5 years, were studied with the aim to give the best definition of erosive disease. A decision was made to select a definition with a high specificity and focus on patients who did not otherwise fulfil the 2010 ACR/EULAR RA criteria (<6 points). By a unanimous vote the following definition was selected: erosive disease for use in the 2010 ACR/EULAR RA classification criteria is defined when an erosion (defined as a cortical break) is seen in at least three separate joints at any of the following sites: the proximal interphalangeal, the metacarpophalangeal, the wrist (counted as one joint) and the metatarsophalangeal joints on radiographs of both hands and feet. A highly specific definition for erosive disease has thus been formulated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23378540     DOI: 10.1136/annrheumdis-2012-202779

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  36 in total

1.  Evaluation of the predictive accuracy of MRI-detected erosions in hand and foot joints in patients with undifferentiated arthritis.

Authors:  Debbie M Boeters; Aleid C Boer; Annette H M van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2018-07-31       Impact factor: 19.103

Review 2.  Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings.

Authors:  Alexandros A Drosos; Eleftherios Pelechas; Paraskevi V Voulgari
Journal:  Rheumatol Int       Date:  2019-05-22       Impact factor: 2.631

3.  The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study.

Authors:  Yeliz Özkaya Eker; Ömer Nuri Pamuk; Gülsüm Emel Pamuk; Salim Dönmez; Necati Çakır
Journal:  Eur J Rheumatol       Date:  2014-06-01

4.  Are MRI-detected erosions specific for RA? A large explorative cross-sectional study.

Authors:  Debbie M Boeters; Wouter P Nieuwenhuis; Hanna W van Steenbergen; Monique Reijnierse; Robert B M Landewé; Annette H M van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2018-02-28       Impact factor: 19.103

5.  Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy.

Authors:  Peter M Ten Klooster; Martijn A H Oude Voshaar; Walid Fakhouri; Inmaculada de la Torre; Claudia Nicolay; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2019-06-03       Impact factor: 2.980

6.  Rheumatoid arthritis: erosion defined: back to basics.

Authors:  Jonathan Kay; Ellen M Gravallese
Journal:  Nat Rev Rheumatol       Date:  2013-04-23       Impact factor: 20.543

7.  ACPA-positive versus ACPA-negative rheumatoid arthritis: two distinct erosive disease entities on radiography and ultrasonography.

Authors:  Julien Grosse; Edem Allado; Camille Roux; Audrey Pierreisnard; Marion Couderc; Isabelle Clerc-Urmes; Thomas Remen; Éliane Albuisson; Marcelo De Carvalho-Bittencourt; Isabelle Chary-Valckenaere; Damien Loeuille
Journal:  Rheumatol Int       Date:  2019-12-13       Impact factor: 2.631

8.  Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Raphaèle Seror; Hendrika Bootsma; Simon J Bowman; Thomas Dörner; Jacques-Eric Gottenberg; Xavier Mariette; Elke Theander; Stefano Bombardieri; Salvatore De Vita; Thomas Mandl; Wan-Fai Ng; Aike Kruize; Athanasios Tzioufas; Claudio Vitali
Journal:  Rheumatology (Oxford)       Date:  2015-07-31       Impact factor: 7.580

9.  A double-blind placebo-controlled randomized trial of oral saffron in the treatment of rheumatoid arthritis.

Authors:  Maryam Sahebari; Hossein Heidari; Shima Nabavi; Mandana Khodashahi; Zahra Rezaieyazdi; Maliheh Dadgarmoghaddam; Hossein Hosseinzaheh; Shaghayegh Abbasi; Kamila Hashemzadeh
Journal:  Avicenna J Phytomed       Date:  2021 Jul-Aug

10.  In Rheumatoid Arthritis Patients, HLA-DRB1*04:01 and Rheumatoid Nodules Are Associated With ACPA to a Particular Fibrin Epitope.

Authors:  Guillaume Larid; Mikael Pancarte; Géraldine Offer; Cyril Clavel; Marielle Martin; Vincent Pradel; Isabelle Auger; Pierre Lafforgue; Jean Roudier; Guy Serre; Nathalie Balandraud
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.